Modelling the impact of treatment with individual antiretrovirals

Current Opinion in HIV and AIDS

Volumn 6, Issue 2, 2011, Pages 124-130

  Cambiano, Valentina ^a   Phillips, Andrew N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antiretroviral therapy (ART); HIV; Mathematical model

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BONE DISEASE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG CHOICE; EPIDEMIC; GENOTYPE; HETEROSEXUAL MALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INCIDENCE; INFECTION RISK; KIDNEY FUNCTION; LIPODYSTROPHY; MATHEMATICAL MODEL; NONHUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PERIPHERAL NEUROPATHY; PREDICTION; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SCREENING TEST; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; TOXIC HEPATITIS; TRANSSEXUALISM; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79951770250     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328343ad66     Document Type: Article

References (64)

1. Miiro G, Todd J, Mpendo J, et al. Reduced morbidity and mortality in the first year after initiating highly active antiretroviral therapy (HAART) among Ugandan adults. Trop Med Int Health 2009; 14:556-563.
2. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008; 371:1603-1611. (Pubitemid 351626844)
3. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. J Am Med Assoc 1998; 279:450-454. (Pubitemid 28082255)
4. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730. (Pubitemid 28534954)
5. Castilla J, Del RJ, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96-101. (Pubitemid 41233212)
6. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection andCD4cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-733. (Pubitemid 27417971)
7. Zhang LQ, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340:1605-1613. (Pubitemid 29249429)
8. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415-421. (Pubitemid 30182438)
9. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIVinfection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000; 14:117-121. (Pubitemid 30116436)
10. Kotler DP, Shimada T, Snow G, et al. Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis. AIDS 1998; 12:597-604. (Pubitemid 28162098)
11. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180. (Pubitemid 24331334)
12. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802. (Pubitemid 29415583)
13. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. J Am Med Assoc 2000; 283:1175-1182. (Pubitemid 30126606)
14. Reina JJ, Bernardi A, Clerici M, Rojo J. HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors. Future Medicinal Chem 2010; 2:1141-1159.
15. Karim QA, Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
16. Centers for Disease Control and Prevention. Extended safety study of tenofovir disoproxil fumarate (TDF) among HIV-1 negative men. ClinicalTrials gov 2010 January 6Available from: URL:
17. Centers for Disease Control and Prevention. Bangkok Tenofovir Study. ClinicalTrials gov 2010 January 6Available from: URL: . gov/ct2/show/NCT00119106
18. Centers for Disease Control and Prevention. Botswana TDF/FTC Oral HIV Prophylaxis Trial. ClinicalTrials gov 2007 April 2.
19. iPrEx. www globaliprex net 2010 November 1Available from: URL:
20. Partners PrEP Study. University of Washington 2010 November 1Available from: URL:
21. Centers for Disease Control and Prevention. FEM-PrEP (Truvada1): study to assess the role of Truvada1 in preventing HIV acquisition in women. ClinicalTrials gov 2010 October 28Available from: URL:
22. Microbicide trial network. Phase 2B safety and effectiveness study of tenofovir 1% gel, tenofovir disoproxil fumarate tablet and emtricitabine/ tenofovir disoproxil fumarate tablet for the prevention of HIV infection in women.Microbicide trial network 2010 November 1Available from: URL:
23. Hughes CA, Robinson L, Tseng A, MacArthur RD. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Exp Opin Pharmacother 2009; 10:2445-2466.
24. Nolan D, Reiss P, Mallal S, Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opin Drug Saf 2005; 4:201-218. (Pubitemid 40867334)
25. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nature Rev Drug Discov 2003; 2:624-634. (Pubitemid 37361766)
26. Gray RH, Li X, Wawer MJ, et al. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission: Rakai, Uganda. AIDS 2003; 17:1941-1951. (Pubitemid 37070280)
27. Bender MA, Kumarasamy N, Mayer KH, et al. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis 2010; 50:416-425.
28. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings: the case of Cô te d'Ivoire. N Engl J Mede 2006; 355:1141-1153. (Pubitemid 44394920)
29. Wolf LL, Ricketts P, Freedberg KA, et al. The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean. J Acquir Immune Defic Syndr 2007; 46:463-471. (Pubitemid 350098698)
30. Law MG, Prestage G, Grulich A, et al. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2001; 15:1287-1294. (Pubitemid 32592362)
31. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287:650-654. (Pubitemid 30070912)
32. Schackman BR, Scott CA, Sax PE, et al. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis 2007; 45:1062-1070. (Pubitemid 47580359)
33. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-19.
34. Roberts MS, Nucifora KA, Braithwaite RS. Using mechanistic models to simulate comparative effectiveness trials of therapy and to estimate long-term outcomes in HIV care. Medical Care 2010; 48:S90-S95.
35. Braithwaite RS, Roberts MS, Goetz MB, et al. Do benefits of earlier antiretroviral treatment initiation outweigh harms for individuals at risk for poor adherence? Clin Infect Dis 2009; 48:822-826.
36. Phillips AN, Sabin C, Pillay D, Lundgren JD. HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Med 2007; 8:536-546. (Pubitemid 47616833)
37. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-831. (Pubitemid 32222162)
38. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Medical Care 2006; 44:990-997. (Pubitemid 44674030)
39. Schackman BR, Freedberg KA, Weinstein MC, et al. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Internal Med 2002; 162:2478-2486. (Pubitemid 35340465)
40. Schackman BR, Scott CA, Walensky RP, et al. The cost-effectiveness of HLAB-5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008; 22:2025-2033.
41. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States: an analysis of cost-effectiveness. N Engl J Med 2005; 352:586-595. (Pubitemid 40204671)
42. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and costeffectiveness. Clin Infect Dis 2009; 48:806-815.
43. Walensky RP, Paltiel AD, Losina E, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 2010; 51:392-400.
44. Kimmel AD, Weinstein MC, Anglaret X, et al. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 2010; 54:258-268.
45. Losina E, Touré H, Uhler LM, et al. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Cô te d'Ivoire appraisal. PloS Med 2009; 6: [Epub ahead of print].
46. Yazdanpanah Y, Losina E, Anglaret X, et al. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIVAIDS in Cô te d'Ivoire: a trial-based analysis. AIDS 2005; 19:1299-1308. (Pubitemid 41224899)
47. Yazdanpanah Y, Wolf LL, Anglaret X, et al. CD4' T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. Antiv Ther 2010; 15:351-361.
48. Walensky RP, Wood R, Weinstein MC, et al. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 2008; 197:1324-1423.
49. Walensky RP, Wood R, Fofana MO, et al. The clinical impact and costeffectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr 2010 (published online).
50. Walensky RP, Wolf LL, Wood R, et al. When to start antiretroviral therapy in resource-limited settings. Ann Internal Med 2009; 151:157-238.
51. Freedberg KA, Kumarasamy N, Losina E, et al. Clinical impact and costeffectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 2007; 21 (Suppl 4):S117-S128. (Pubitemid 47051757)
52. Yazdanpanah Y, Vray M, Meynard J, et al. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med 2007; 8:439-450. (Pubitemid 47336785)
53. Rydzak CE, Cotich KL, Sax PE, et al. Assessing the performance of a computer-based policy model of HIV and AIDS. PloS One 2010; 5: iie12647.
54. Braithwaite RS, Justice AC, Chang CCH, et al. Estimating the proportion of patients infected with HIV who wilt die of comorbid diseases. Am JMed 2005; 118:890-898. (Pubitemid 41097468)
55. Braithwaite RS, Conigliaro J, Roberts MS, et al. Estimating the impact of alcohol consumption on survival for HIV plus individuals. Aids Care-Psycholog Socio-Medical Aspects AIDS/HIV 2007; 19:459-466. (Pubitemid 46598742)
56. Braithwaite RS, Shechter S, Roberts MS, et al. Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation. J Antimicrob Chemother 2006; 58:1036-1043.
57. Bansi L, Sabin C, Delpech V, et al. Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations-. HIV Med 2010; 11:432-438.
58. Phillips AN, Pillay D, Miners AH, et al. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371:1443-1451. (Pubitemid 351635534)
59. Phillips AN, Pillay D, Garnett G, et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first- to second-line antiretroviral regimens in resource-limited settings. AIDS 2010 [Epub ahead of print].
60. Smith RJ, Okano JT, Kahn JS, et al. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science 2010; 327:697-701.
61. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PloS One 2007; 2:e875.
62. Westreich D, Eron J, Behets F, et al. Survival in women exposed to singledose nevirapine for prevention of mother-to-child transmission of HIV: a stochastic model. J Infect Dis 2007; 195:837-846. (Pubitemid 46363929)
63. Braithwaite RS, Shechter S, Chang CCH, et al. Estimating the rate of accumulating drug resistance mutations in the HIV genome. Value Health 2007; 10:204-213. (Pubitemid 46802278)
64. Anderson RM, Garnett GP. Mathematical models of the transmission and control of sexually transmitted diseases. Sex Transm Dis 2000; 27:636-643.